CellarisBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CellarisBio is a private, early-stage biotech tools company commercializing its proprietary MICRO-TAG® platform for cellular target engagement analysis. The platform allows researchers to directly quantitate ligand-target interactions inside intact cells using standard lab equipment, addressing a critical bottleneck in early-stage drug discovery for challenging target classes. The company currently generates early revenue by selling reagent kits and offering collaborative study solutions, positioning itself as an enabler for pharmaceutical and biotech R&D rather than developing its own therapeutic pipeline.

Cell TherapyBiologics

Technology Platform

MICRO-TAG® Cellular Target Engagement platform, based on enzyme complementation chemistry, enabling quantitative, real-time measurement of ligand-target binding inside intact, living cells using standard lab equipment.

Opportunities

The platform addresses a critical need for physiologically relevant data in early drug discovery, particularly for challenging target classes like transcription factors and protein complexes.

Its compatibility with DNA-Encoded Library screening and multiple therapeutic modalities positions it well within high-growth areas of pharmaceutical R&D.

Risk Factors

Key risks include slow adoption against established assay workflows, competition from larger life science tools companies, and reliance on a single technology platform.

As a young private company, it also faces execution and funding risks in scaling its commercial operations.

Competitive Landscape

CellarisBio competes in the cell-based assay and drug discovery tools market against large, established players like Promega and Revvity, as well as other startups. Its differentiation lies in the direct quantification of cellular target engagement in real-time, a niche with limited direct competitors but many adjacent solutions for cellular analysis.

More companies in Biologics / Biosimilars →More companies in United States →